Skip to main content

Advertisement

Log in

Intravenous immunoglobulin for the treatment of intractable cholangitis after Kasai portoenterostomy in biliary atresia patients

  • Original Article
  • Published:
Pediatric Surgery International Aims and scope Submit manuscript

Abstract

Objective

To assess the efficacy of intravenous immunoglobulin (IVIG) as add-on treatment for intractable cholangitis (IC) after Kasai portoenterostomy (KPE) in biliary atresia (BA) patients.

Methods

113 BA patients who had one or more episodes of cholangitis after KPE were recruited in this study. According to whether response to routine conservative treatment, all patients were divided into IC group and simple cholangitis (SC) group. Meanwhile, patients with IC subdivided into IVIG group and control group according to whether application of IVIG.

Results

The IC group had higher serum procalcitonin (PCT) (P = 0.014), C-reactive protein (CRP) (P = 0.023), and γ-Gltamyltranspeptidase (γ-GGT) (P = 0.031) level than the SC group. The IVIG group had shorter duration of fever after treatment (P = 0.011) and length of hospital stay (P = 0.018) than the control group. The time until recurrent episode of cholangitis was significant longer in IVIG group than in control group (P = 0.019).

Conclusions

IVIG as add-on treatment may be an effective treatment for the cholangitis acute episode, and we conclude by calling for more prospective studies to attest to the role of IVIG in the treatment of cholangitis.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Fig. 1

Similar content being viewed by others

Abbreviations

BA:

Biliary atresia

KPE:

Kasai portoenterostomy

IVIG:

Intravenous immunoglobulin

IC:

Intractable cholangitis

ALT:

Alanine transaminase

AST:

Aspartate transaminase

SC:

Simple cholangitis

PCT:

Procalcitonin

CRP:

C-reactive protein

γ-GGT:

γ-Gltamyltranspeptidase

WBC:

White blood cell count

References

  1. Kasahara M, Umeshita K, Sakamoto S el at (2017) Liver transplantation for biliary atresia: a systematic review. Pediatr Surg Int 33:1289–1295

    Article  PubMed  Google Scholar 

  2. Bessho K, Bezerra JA (2011) Biliary atresia: will blocking inflammation tame the disease? Annu Rev Med 62:171–185

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  3. Hartley JL, Davenport M, Kelly DA (2009) Biliary atresia. Lancet 374:1704–1713

    Article  PubMed  Google Scholar 

  4. Ecoffey C, Rothman E, Bernard O et al (1987) Bacterial cholangitis after surgery for biliary atresia. J Pediatr 111: 824–829

    Article  CAS  PubMed  Google Scholar 

  5. Wu ET, Chen HL, Ni YH, el at (2001) Bacterial cholangitis in patients with biliary atresia: impact on short-term outcome. Pediatr Surg Int 17:390–395

    Article  CAS  PubMed  Google Scholar 

  6. Ernest VHL, Saing H, Tam PK (2003) Cholangitis after hepatic portoenterostomy for biliary atresia: a multivariate analysis of risk factors. J Pediatr 142:566–571

    Article  Google Scholar 

  7. Liu J, Li G, Lai B (1997) A study on cholangitis after hepatic portoenterostomy for biliary atresia. Chin Med J (Engl) 110:335–337

    CAS  Google Scholar 

  8. Ohkohchi N, Chiba T, Ohi R et al (1989) Long-term follow-up study of patients with cholangitis after successful Kasai operation in biliary atresia: selection of recipients for liver transplantation. J Pediatr Gastroenterol Nutr 9:416–420

    Article  CAS  PubMed  Google Scholar 

  9. Davenport M (2017) Adjuvant therapy in biliary atresia: hopelessly optimistic or potential for change? Pediatr Surg Int 33:1263–1273

    Article  PubMed  Google Scholar 

  10. Gomi H, Solomkin JS, Takada T el at (2013) TG13 antimicrobial therapy for acute cholangitis and cholecystitis. J Hepatobiliary Pancreat Sci 20:60–70

    Article  PubMed  Google Scholar 

  11. Hureau M, Saint-Leger P (2018) Intravenous immunoglobulin therapy in non-menstrual staphylococcal toxic shock syndrome. Med Mal Infect 48:70–72

    Article  CAS  PubMed  Google Scholar 

  12. Stump SE, Schepers AJ, Jones AR et al (2017) Comparison of weight based dosing strategies for intravenous immunoglobulin in patients with hematologic malignancies. Pharmacotherapy 37:1530–1536

    Article  CAS  PubMed  Google Scholar 

  13. Komori T, Dainichi T, Kusuba N et al (2017) Efficacy of intravenous immunoglobulins for the treatment of mucous membrane pemphigoid-like epidermolysis bullosa acquisita. Eur J Dermatol 27:563–564

    PubMed  Google Scholar 

  14. Iro MA, Martin NG, Absoud M el at (2017) Intravenous immunoglobulin for the treatment of childhood encephalitis. Cochrane Database Syst Rev 10:D11367

    Google Scholar 

  15. Pourpak Z, Aghamohammadi A, Sedighipour L et al (2006) Effect of regular intravenous immunoglobulin therapy on prevention of pneumonia in patients with common variable immunodeficiency. J Microbiol Immunol Infect 39: 114–120

    CAS  PubMed  Google Scholar 

  16. Fenner EK, Boguniewicz J, Tucker RM et al (2014) High-dose IgG therapy mitigates bile duct-targeted inflammation and obstruction in a mouse model of biliary atresia. Pediatr Res 76: 72–80

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  17. Lages CS, Simmons J, Chougnet CA et al (2012) Regulatory T cells control the CD8 adaptive immune response at the time of ductal obstruction in experimental biliary atresia. Hepatology 56: 219–227

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  18. Okamura A, Harada K, Nio M et al (2013) Participation of natural killer cells in the pathogenesis of bile duct lesions in biliary atresia. J Clin Pathol 66:99–108

    Article  CAS  PubMed  Google Scholar 

  19. Chiang LW, Lee CY, Krishnaswamy G et al (2017) Seventeen years of Kasai portoenterostomy for biliary atresia in a single Southeast Asian paediatric centre. J Paediatr Child Health 53:412–415

    Article  PubMed  Google Scholar 

  20. Webb NL, Jiwane A, Ooi CY et al (2017) Clinical significance of liver histology on outcomes in biliary atresia. J Paediatr Child Health 53: 252–256

    Article  PubMed  Google Scholar 

  21. Mones RL, DeFelice AR, Preud’Homme D (1994) Use of neomycin as the prophylaxis against recurrent cholangitis after Kasai portoenterostomy. J Pediatr Surg 29:422–424

    Article  CAS  PubMed  Google Scholar 

  22. Ljungh A, Wadstrom T (2002) The role of microorganisms in biliary tract disease. Curr Gastroenterol Rep 4:167–171

    Article  PubMed  Google Scholar 

  23. Decharun K, Leys CM, West KW et al (2016) Prophylactic antibiotics for prevention of cholangitis in patients with biliary atresia status post-kasai portoenterostomy: a systematic review. Clin Pediatr (Phila) 55:66–72

    Article  Google Scholar 

  24. Uzzan B, Cohen R, Nicolas P et al (2006) Procalcitonin as a diagnostic test for sepsis in critically ill adults and after surgery or trauma: a systematic review and meta-analysis. Crit Care Med 34:1996–2003

    Article  CAS  PubMed  Google Scholar 

  25. Roopenian DC, Akilesh S (2007) FcRn: the neonatal Fc receptor comes of age. Nat Rev Immunol 7:715–725

    Article  CAS  PubMed  Google Scholar 

  26. Tha-In T, Bayry J, Metselaar HJ et al (2008) Modulation of the cellular immune system by intravenous immunoglobulin. Trends Immunol 29:608–615

    Article  CAS  PubMed  Google Scholar 

  27. Durandy A, Kaveri SV, Kuijpers TW et al (2009) Intravenous immunoglobulins–understanding properties and mechanisms. Clin Exp Immunol 158(Suppl 1):2–13

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  28. Esposito S, De Simone G, Boccia G et al (2017) Sepsis and septic shock: new definitions, new diagnostic and therapeutic approaches. J Glob Antimicrob Resist 10: 204–212

    Article  PubMed  Google Scholar 

Download references

Funding

This study was supported by grants from the National Natural Science Foundation of China (no. 81571478).

Author information

Authors and Affiliations

Authors

Corresponding author

Correspondence to Jiexiong Feng.

Ethics declarations

Conflict of interest

The authors declare that they have no conflict of interest.

Ethical approval

The Institutional Review Board of Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology approved the protocol of the study (Permit Number 2010-HP0761, Wuhan, China). All procedures performed in studies involving human participants were in accordance with the ethical standards of the institutional and/or national research committee and with the 1964 Helsinki declaration and its later amendments or comparable ethical standards.

Informed consent

Written informed consent was obtained from the guardians of the patients included in this study.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Li, D., Wang, P., He, Y. et al. Intravenous immunoglobulin for the treatment of intractable cholangitis after Kasai portoenterostomy in biliary atresia patients. Pediatr Surg Int 34, 399–404 (2018). https://doi.org/10.1007/s00383-018-4240-6

Download citation

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00383-018-4240-6

Keywords

Navigation